In May 2012, the U.S. Preventive Services Task Force recommended against routine PSA screening (Prostate-Specific Antigen test to screen Prostatecancer) before being diagnosed as it did not benefit patients.
Fortunately, earlier diagnosis of prostatecancer, thanks to prostate-specific antigen (PSA) testing, may have slowed and even reversed these trends, according to the study, which was published in the Journal of the National Cancer Institute.
The biotechnology firm announced that a much-awaited study of its bone drug Xgeva (also known as denosumab, and sold for osteoporosis as Prolia) prevented prostatecancer from spreading to the bone in patient whose levels of prostate-specific antigen are rising.